Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › tenecteplase

tenecteplase

14 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of tenecteplase

13 trials tracked of tenecteplase: 10 in phase 3 or 4 and 5 with published results. The most-cited published study has 193 citations.

13Trials tracked
10Phase 3 & 4
0Recruiting
5With published results
Phase distribution
Phase 4 1 Phase 3 9 Phase 2 3
  1. Phase 3 Tenecteplase in Stroke Patients Between 4.5 and 24 Hours Completed · 193 cited
  2. Phase 3 A Randomized Controlled Trial of TNK-tPA Versus Standard of Care for Minor Ischemic Stroke With Proven Occlusion Completed · 131 cited
  3. Phase 3 A Study in Chinese Patients to Compare How Tenecteplase and Alteplase Given After a Stroke Improve Recovering of Physical Activity Completed · 90 cited
  4. Phase 4 STrategic Reperfusion in Elderly Patients Early After Myocardial Infarction Completed · 54 cited
  5. Phase 3 STREAM-Strategic Reperfusion (With Tenecteplase and Antithrombotic Treatment) Early After Myocardial Infarction Completed · 7 cited
  6. Phase 3 Single Bolus Recombinant Nonimmunogenic Staphylokinase Versus Single Bolus Tenecteplase (Metalyse) in STEMI Completed
Show 7 more trials
  1. Phase 3 A Study of Tenecteplase for Restoration of Function in Dysfunctional Central Venous Catheters Completed
  2. Phase 3 A Study of Tenecteplase for Restoration of Function in Dysfunctional Hemodialysis (HD) Catheters Completed
  3. Phase 3 A Study of Tenecteplase for Restoration of Function in Dysfunctional Hemodialysis Catheters Completed
  4. Phase 3 A Study of Tenecteplase for Restoration of Function in Dysfunctional Central Venous Catheters Completed
  5. Phase 2 TNK-tPA Evaluation for Minor Ischemic Stroke With Proven Occlusion Completed
  6. Phase 2 A Safety/Efficacy Study of Intra-coronary Tenecteplase During Balloon Angioplasty to Treat Heart Attacks Completed
  7. Phase 2 Tenecteplase in Patients With COVID-19 Completed

Showing the 13 most-cited and recently-updated of 13 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Intravenous tenecteplase improves functional outcomes but increases hemorrhage risk in non-large vessel occlusion acute ischemic stroke
Neurology RCT
Intravenous tenecteplase improves functional outcomes but increases hemorrhage risk in non-large vessel occlusion acute ischemic stroke Tenecteplase improves stroke recovery but increases bleeding risk in late treatment window
This randomized, open-label, blinded end-point trial evaluated intravenous tenecteplase versus standard medical treatment in 570 patients wi…
Tenecteplase helps late-arriving stroke patients recover better but raises bleeding risk, giving doctors a new tool for those beyond the usu…
JAMA Apr 9, 2026
Reteplase and non-immunogenic staphylokinase show superior functional outcomes vs alteplase in AIS within 4.5h
Neurology Meta-analysis
Reteplase and non-immunogenic staphylokinase show superior functional outcomes vs alteplase in AIS within 4.5h Which clot-busting drug works best for stroke? Two newer options may help more people walk and talk normally again
A network meta-analysis of 21 RCTs (n=16,837) found reteplase (18+18 mg) and non-immunogenic recombinant staphylokinase (10 mg) were associa…
Two newer clot-busting drugs help more stroke patients walk and talk normally again without increasing the risk of dying within 90 days.
Frontiers Mar 30, 2026